HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Tumor viruses, also known as oncogenic viruses, have been identified as significant contributors to the development of certain cancers. These viruses possess the ability to integrate their genetic material into the host's DNA, disrupting normal cellular functions and potentially leading to the uncontrolled growth characteristic of cancerous cells. Understanding the intricate relationship between viruses and cancer is crucial in advancing both preventive strategies and therapeutic interventions.
Several viruses have been identified as having oncogenic potential. Human papillomavirus (HPV), linked to cervical and other genital cancers, is one such example. Hepatitis B and C viruses are associated with liver cancer, while Epstein-Barr virus (EBV) is implicated in various lymphomas and nasopharyngeal carcinoma. Human T-cell lymphotropic virus type 1 (HTLV-1) has been linked to adult T-cell leukemia/lymphoma. These viruses employ diverse mechanisms to promote cancer development, ranging from the integration of viral genes into the host genome to the disruption of cellular regulatory pathways.
Efforts to prevent virus-induced cancers often focus on vaccination and antiviral treatments. Vaccination programs targeting viruses like HPV have proven successful in reducing the incidence of associated cancers. Antiviral medications can also help control viral infections and lower the risk of associated cancers. Additionally, ongoing research explores innovative therapies, including immunotherapies, to harness the body's immune system in combating virus-associated cancers. Early detection through screening and monitoring individuals at high risk for virus-related cancers remains a crucial aspect of comprehensive cancer control.
